Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Pang, Tao ^a   Wang, Juan ^a   Benicky, Julius ^a   Sánchez Lemus, Enrique ^a   Saavedra, Juan M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Angiotensin ii at1 receptor blockers; Cortical neurons; COX 2; IL 1 neurotoxicity; JNK activation; Neuronal inflammation; Neuroprotection; Oxidative stress; Sk n sh neuroblasts

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; ABC TRANSPORTER G1; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CANDESARTAN; CD36 ANTIGEN; CYCLOOXYGENASE 2; DICHLORODIHYDROFLUORESCEIN DIACETATE; HYDROGEN PEROXIDE; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; LOSARTAN; LUCIGENIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; STRESS ACTIVATED PROTEIN KINASE; TELMISARTAN;

ABCG1 GENE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CELL; CD36 GENE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME INDUCTION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; NERVE CELL; NEUROBLAST; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84861466194     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-102     Document Type: Article

References (76)

1. Vitkovic L, Bockaert J, Jacque C. " Inflammatory" cytokines: neuromodulators in normal brain?. J Neurochem 2000, 74:457-471.
2. Pinteaux E, Trotter P, Simi A. Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation. Cytokine 2009, 45:1-7. 10.1016/j.cyto.2008.10.008, 19026559.
3. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002, 20:S1-S13.
4. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeuric target. Trends Neurosci 2000, 23:618-625. 10.1016/S0166-2236(00)01661-1, 11137152.
5. Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 2003, 17:152-157. 10.1016/S0889-1591(02)00098-3, 12706413.
6. Pascoe MC, Crewther SG, Carey LM, Crewther DP. Inflammation and depression: why poststroke depression may be the norm and not the exception. Int J Stroke 2011, 6:128-135. 10.1111/j.1747-4949.2010.00565.x, 21371275.
7. Wang P, Rothwell NJ, Pinteaux E, Brough D. Neuronal injury induces the release of pro-interleukin-1beta from activated microglia in vitro. Brain Res 2008, 1236:1-7.
8. Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010, 7:354-365. 10.1016/j.nurt.2010.05.014, 2951017, 20880500.
9. Thornton P, McColl BW, Cooper L, Rothwell NJ, Allan SM. Interleukin-1 drives cerebrovascular inflammation via MAP kinase-independent pathways. Curr Neurovasc Res 2010, 7:330-340.
10. Brown GC, Neher JJ. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010, 41:242-247. 10.1007/s12035-010-8105-9, 20195798.
11. Nimmo AJ, Vink R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat CNS Drug Discov 2009, 4:86-95. 10.2174/157488909788452997, 19519558.
12. Skinner RA, Gibson RM, Rothwell NJ, Pinteaux E, Penny JI. Transport of interleukin-1 across cerebromicrovascular endothelial cells. Br J Pharmacol 2009, 156:1115-1123. 10.1111/j.1476-5381.2008.00129.x, 2697691, 19298391.
13. Denes A, Pinteaux E, Rothwell NJ, Allan SM. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis 2011, 32:517-527. 10.1159/000332205, 22104408.
14. Zhang ZH, Yu Y, Wei SG, Felder RB. Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling. J Hypertens 2010, 28:806-816. 10.1097/HJH.0b013e3283358b6e, 2929929, 20027123.
15. Benicky J, Sánchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, Leng Y, Chuang DM, Saavedra JM. Angiotensin II AT(1) receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011, 36:857-870. 10.1038/npp.2010.225, 3055735,3055735, 21150913.
16. Kang YM, Zhang ZH, Xue B, Weiss RM, Felder RB. Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure. Am J Physiol Heart Circ Physiol 2008, 295:H227-H236. 10.1152/ajpheart.01157.2007, 2494768, 18487441.
17. Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol Aging 2012, 33(204):e1-11.
18. Saavedra JM, Sánchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT(1) receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology 2011, 36:1-18. 10.1016/j.psyneuen.2010.10.001, 2998923, 21035950.
19. Saavedra JM. Angiotensin II AT(1) Receptor Blockers Ameliorate Inflammatory Stress: A Beneficial Effect for the Treatment of Brain Disorders. Cell Mol Neurobiol in press.
20. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004, 35:1726-1731. 10.1161/01.STR.0000129788.26346.18, 15143297.
21. Lou M, Blume A, Zhao Y, Gohlke P, Deuschl G, Herdegen T, Culman J. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 2004, 24:536-547.
22. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2004, 311:989-995. 10.1124/jpet.104.072066, 15302895.
23. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. J Hypertens 2010, 28:1730-1737. 10.1097/HJH.0b013e32833a551a, 20498620.
24. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 2005, 25:878-886. 10.1038/sj.jcbfm.9600082, 15729290.
25. Kobayashi T, Kawamata T, Shibata N, Okada Y, Kobayashi M, Hori T. Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A(2) level in experimental stroke. J Neurotrauma 2009, 26:2355-2364. 10.1089/neu.2009.0965, 19604102.
26. Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H, Stern DM, Matsuyama T. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res 2010, 1340:70-80.
27. Thoene-Reineke C, Rumschüssel K, Schmerbach K, Krikov M, Wengenmayer C, Godes M, Mueller S, Villringer A, Steckelings U, Namsolleck P, Unger T. Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models. PLoS One 2011, 6:e23646. 10.1371/journal.pone.0023646, 3161992, 21901125.
28. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, Park DK, Sinn DI, Kim JM, Kim M, Roh JK. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007, 322:1051-1058. 10.1124/jpet.107.120097, 17538008.
29. Lanz TV, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, Axtell R, Zhang H, Platten M, Wyss-Coray T, Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest 2010, 120:2782-2794. 10.1172/JCI41709, 2912186, 20628203.
30. Mertens B, Vanderheyden P, Michotte Y, Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. J Renin Angiotensin Aldosterone Syst 2010, 11:49-56. 10.1177/1470320309347789, 19861346.
31. Garrido-Gil P, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J Neuroinflammation 2012, 9:38. 10.1186/1742-2094-9-38, 3298706, 22356806.
32. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009, 54:782-787. 10.1161/HYPERTENSIONAHA.109.136879, 19635982.
33. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010, 13:195-201. 10.1089/rej.2009.0944, 20370487.
34. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 2009, 109:656-669. 10.1111/j.1471-4159.2009.05999.x, 19245663.
35. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008, 31:58-73. 10.1016/j.nbd.2008.03.003, 18499466.
36. Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D, Rachubinski AL, Das M, Griffin WS, Jones SM. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J Neuroinflammation 2011, 8:129. 10.1186/1742-2094-8-129, 3198931, 21975039.
37. Hoozemans JJ, Veerhuis R, Janssen I, Rozemuller AJ, Eikelenboom P. Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp Gerontol 2001, 36:559-570. 10.1016/S0531-5565(00)00226-6, 11250126.
38. Fiebich BL, Mueksch B, Boehringer M, Hüll M. Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB. J Neurochem 2000, 75:2020-2028.
39. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002. 10.1161/01.HYP.0000123072.34629.57, 15007034.
40. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006, 45:154-162. 10.1016/j.vph.2006.05.002, 16765099.
41. Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through PPARγ activation in human monocytes. J Hypertens 2012, 30:87-96. 10.1097/HJH.0b013e32834dde5f, 3237779, 22124178.
42. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997, 42:159-163. 10.1002/ana.410420205, 9266724.
43. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000, 52:415-472.
44. Mogi M, Li JM, Iwanami J, Min LJ, Tsukuda K, Iwai M, Horiuchi M. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006, 48:141-148. 10.1161/01.HYP.0000229648.67883.f9, 16769992.
45. Zhao Y, Foryst-Ludwig A, Bruemmer D, Culman J, Bader M, Unger T, Kintscher U. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J Neurochem 2005, 94:1395-1401. 10.1111/j.1471-4159.2005.03275.x, 15992368.
46. Im JY, Kim D, Paik SG, Han PL. Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. Free Radic Biol Med 2006, 41:960-972. 10.1016/j.freeradbiomed.2006.06.001, 16934679.
47. Tammariello SP, Quinn MT, Estus S. NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. J Neurosci 2000, 20:RC53.
48. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 1995, 95:1669-1675. 10.1172/JCI117842, 295674, 7706475.
49. Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 2005, 175:5423-5429.
50. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000, 28:149-167.
51. Li Q, Engelhardt JF. Interleukin-1beta induction of NFkappaB is partially regulated by H2O2-mediated activation of NFkappaB-inducing kinase. J Biol Chem 2006, 281:1495-1505.
52. Chen H, Kim GS, Okami N, Narasimhan P, Chan PH. NADPH oxidase is involved in post-ischemic brain inflammation. Neurobiol Dis 2011, 42:341-348. 10.1016/j.nbd.2011.01.027, 3079796, 21303700.
53. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008, 198:22-28. 10.1016/j.atherosclerosis.2007.09.013, 17950296.
54. Hancock JT, Jones OT. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J 1987, 242:103-107. 1147670, 3036079.
55. Stuehr DJ, Fasehun OA, Kwon NS, Gross SS, Gonzalez JA, Levi R, Nathan CF. Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J 1991, 5:98-103.
56. Yamamoto E, Tamamaki N, Nakamura T, Kataoka K, Tokutomi Y, Dong YF, Fukuda M, Matsuba S, Ogawa H, Kim-Mitsuyama S. Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. Stroke 2008, 39:3049-3056. 10.1161/STROKEAHA.108.517284, 18688015.
57. Pelisch N, Hosomi N, Ueno M, Nakano D, Hitomi H, Mogi M, Shimada K, Kobori H, Horiuchi M, Sakamoto H, Matsumoto M, Kohno M, Nishiyama A. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2011, 24:362-368. 10.1038/ajh.2010.241, 3040273, 21164491.
58. Moolwaney AS, Igwe OJ. Regulation of the cyclooxygenase-2 system by interleukin-1beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells. Brain Res Mol Brain Res 2005, 137:202-212.
59. Bourke E, Moynagh PN. Antiinflammatory effects of glucocorticoids in brain cells, independent of NF-kappa B. J Immunol 1999, 163:2113-2119.
60. Petrova TV, Akama KT, Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A 1999, 96:4668-4673. 10.1073/pnas.96.8.4668, 16390, 10200320.
61. Bernardo A, Levi G, Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 2000, 12:2215-2223. 10.1046/j.1460-9568.2000.00110.x, 10947800.
62. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000, 20:558-567.
63. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 2011, 8:91. 10.1186/1742-2094-8-91, 3166925, 21819568.
64. An J, Nakajima T, Kuba K, Kimura A. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertens Res 2010, 33:831-835. 10.1038/hr.2010.79, 20505677.
65. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 2006, 24:1809-1816. 10.1097/01.hjh.0000242405.68461.84, 16915030.
66. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006, 552:112-122. 10.1016/j.ejphar.2006.08.062, 1764497, 17064684.
67. Subramanian V, Golledge J, Heywood EB, Bruemmer D, Daugherty A. Regulation of peroxisome proliferator-activated receptor-γ by angiotensin II via transforming growth factor-β1-activated p38 mitogen-activated protein kinase in aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2012, 32:397-405. 10.1161/ATVBAHA.111.239897, 22095985.
68. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, Dole W, Rutledge JC. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002, 11:21-30.
69. Yatabe J, Sanada H, Yatabe MS, Hashimoto S, Yoneda M, Felder RA, Jose PA, Watanabe T. Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II. Am J Physiol Renal Physiol 2009, 296:F1052-F1060. 10.1152/ajprenal.00580.2007, 19261744.
70. Yasuda N, Akazawa H, Ito K, Shimizu I, Kudo-Sakamoto Y, Yabumoto C, Yano M, Yamamoto R, Ozasa Y, Minamino T, Naito AT, Oka T, Shiojima I, Tamura K, Umemura S, Nemer M, Komuro I. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension 2012, 59:627-633. 10.1161/HYPERTENSIONAHA.111.175208, 22291447.
71. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 2001, 101:2-8.
72. Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ, Morrow JD. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 1999, 53:1495-1498. 10.1212/WNL.53.7.1495, 10534257.
73. Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 1994, 35:592-597. 10.1002/ana.410350513, 7910004.
74. Hoozemans JJ, van Haastert ES, Veerhuis R, Arendt T, Scheper W, Eikelenboom P, Rozemuller AJ. Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J Neuroinflammation 2005, 2:27. 10.1186/1742-2094-2-27, 1308853, 16300681.
75. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011, 26:699-708.
76. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of Angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 340:b5465. 10.1136/bmj.b5465, 2806632, 20068258.